NEW YORK (Reuters Health) – Although trastuzumab is directed against the HER2 protein, patients with HER2-negative breast cancer may also benefit from adjuvant trastuzumab therapy, researchers report. They…
NEW YORK (Reuters Health) – How much an individual patient with esophageal cancer is likely to benefit, if at all, from chemoradiotherapy (CRT) before undergoing esophagectomy can be…
NEW YORK (Reuters Health) – A diagnosis of bladder cancer after an initial presentation with hematuria is often delayed in both men and women – but the delay…
NEW YORK (Reuters Health) – A preoperative MRI showing whether or not a rectal tumor encroaches on the circumferential resection margin (CRM) is a better predictor of recurrence…
NEW YORK (Reuters Health) – While pancreatic cancer mortality is still higher among blacks than whites in the US, rates are decreasing among blacks and increasing among whites,…
NEW YORK (Reuters Health) – In the neoadjuvant treatment of HER2-positive breast cancer, administering trastuzumab concurrently with anthracyclines offers no advantage over sequential administration, according to the results…
NEW YORK (Reuters Health) – Compared to single-agent platinum chemotherapy, platinum-combination chemotherapy improves survival in patients with recurrence of ovarian cancer, a meta-analysis has shown. The researchers say…
NEW YORK (Reuters Health) – Results of a randomized trial conducted in Italy indicate that conventional external radiotherapy (RT) after breast conserving surgery for early breast cancer is…
NEW YORK (Reuters Health) – In hospitalized cancer patients, the common problem of hyponatremia can be corrected by administration of the orally active V2 receptor antagonist, tolvaptan. The…
By Will Boggs, MD NEW YORK (Reuters Health) –In mice, treatment with tumor necrosis factor (TNF) or lymphotoxin makes the blood-brain barrier (BBB) selectively permeable at metastasis sites,…